Trials / Recruiting
RecruitingNCT07067346
Safety & Efficacy of IR-101 in Relapsed/Refractory Neuroblastoma
A Study to Evaluate Safety and Efficacy of Radiopharmaceutical IR-101 in Patients With Relapsed or Refractory Neuroblastoma
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Sichuan University · Academic / Other
- Sex
- All
- Age
- 12 Months
- Healthy volunteers
- Not accepted
Summary
Radiopharmaceutical in Relapsed/Refractory Neuroblastoma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IR-101 | IR-101 Dose Escalation |
Timeline
- Start date
- 2025-07-18
- Primary completion
- 2026-06-30
- Completion
- 2026-06-30
- First posted
- 2025-07-16
- Last updated
- 2025-07-29
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT07067346. Inclusion in this directory is not an endorsement.